| HARMONY (Phase 2b, F2-F3, week 96): MASH resolution | 28mg / 50mg vs placebo | Mar 4, 2024: MASH resolution without worsening of fibrosis of 62% (28mg) and 57% (50mg) vs 24% placebo at week 96 (the trial's week-24 fibrosis-improvement endpoint was the original primary) |
| HARMONY (Phase 2b, F2-F3, week 96): fibrosis improvement | 28mg / 50mg vs placebo | >=1 stage fibrosis improvement without worsening of MASH of 46% (28mg) and 75% (50mg) vs 24% placebo at week 96 |
| SYMMETRY (Phase 2b, F4 compensated cirrhosis, week 96) | 28mg / 50mg vs placebo | Jan 27, 2025: >=1 stage fibrosis improvement (cirrhosis reversal) without worsening of MASH of 29% (28mg) and 39% (50mg) vs 15% placebo at week 96 (completer analysis; ITT 21% / 29% vs 12%); one of the first agents to show fibrosis regression in F4 MASH cirrhosis |
| Non-invasive tests (NIT) across the program | Pooled active arms | Substantial reductions in MRI-PDFF (liver fat), liver stiffness, and serum biomarkers (ALT, AST, Pro-C3); supports the case for FGF21 as a multi-pathway MASH therapy |
| Weight + metabolic effects | Pooled active arms | Modest weight loss plus improved HbA1c and lipid profile; mechanistically distinct from incretin-class weight loss (FGF21 does not act via central satiety pathways) |
| SYNCHRONY Phase 3 program | Three registrational trials | Phase 3 program comprising SYNCHRONY Histology (F2-F3), SYNCHRONY Real-World (F1-F3 / MASLD, non-invasively diagnosed), and SYNCHRONY Outcomes (F4 compensated cirrhosis); evaluates fibrosis improvement, MASH resolution, and long-term liver outcomes; continues under Novo Nordisk ownership |
| Novo Nordisk acquisition (completed Dec 9, 2025) | ~$5.2B total | All-cash $54/share (~$4.7B) plus a non-transferable $6/share CVR (~$0.5B) contingent on US approval of EFX for compensated cirrhosis due to MASH. Akero became a wholly-owned Novo Nordisk subsidiary and was delisted from Nasdaq. Rationale: F4 cirrhotic patients are not addressable by the GLP-1 MASH label, which EFX would cover |
| Mechanistic comparison: FGF21 vs GLP-1 vs THR-beta | Mechanism class | FGF21 (AKRO efruxifermin): direct hepatic + adipose action, fibrosis improvement, modest weight effect. GLP-1 (semaglutide, MASH approval Aug 2025): incretin + central satiety pathway, weight-driven MASH improvement. THR-beta (Madrigal Rezdiffra, MASH approval March 2024): direct hepatic THR-beta action, fibrosis improvement, no weight effect. The three mechanisms are complementary; combination + sequencing strategies are plausible Phase 3 directions |
| Editorial. Why AKRO matters | Strategic context | Akero's efruxifermin was the strongest standalone MASH biotech asset at the time of acquisition. The Novo acquisition gives NVO a multi-mechanism MASH franchise (semaglutide for incretin-responsive F2-F3, efruxifermin for F4 cirrhosis + non-responsive cohorts). The strategic question: does the Novo integration accelerate or slow the EFX Phase 3 timeline, given Novo's commercial focus is GLP-1 while EFX is a non-incretin asset with different launch dynamics? |
Akero Therapeutics